19 September 2018

In British Journal of Radiology Rutger Stijns and colleagues, theme tumors of the digestive tract, showed that using MRI with endorectal filling did not lead to an improved rectal cancer staging and that it has the potential to influence the distance to a key anatomical landmark.

ABSTRACT

Objective:
To assess the influence of endorectal filling (EF) on rectal cancer staging.
Methods:
47 patients who underwent a staging MRI of rectal cancer in the period from 2011 to 2014 were included. The MRI protocol included T2 weighted fast spin echo sequences without and with EF at 3 T (EF-MRI). Images were scored by two readers for T-stage, distance of the lower pole of the tumour to the anorectal junction, distance to the mesorectal fascia (MRF), and number of (suspicious) lymph nodes. Agreement in T-staging was calculated using the Cohen's κ value. Comparison of continuous variables was performed using Wilcoxon matched pairs signed-rank test.
Results:
The interobserver agreement for T-staging with and without EF-MRI showed a poor agreement between both readers (weighted κ = 0.156, weighted κ = 0.037, respectively). Tumours tended to be overstaged more prominently with EF-MRI. The accuracy of predicting the pathological T-stage slightly improved from 55% with EF to 64% without EF for Reader 1 and from 59 to 68% for Reader 2, respectively. The distance of the tumour to the anorectal junction increased from 33.9 to 49.3 mm (p < 0.001) after EF for Reader 2. EF-MRI did not significantly influence the number of (suspicious) lymph nodes and distance to the mesorectal fascia.
Conclusion:
EF-MRI did not lead to an improved tumour staging and it has the potential to influence the distance to a key anatomical landmark. EF-MRI is therefore not recommended in primary staging rectal cancer. Advances in knowledge: EF-MRI may not be used as an additional tool to stage rectal cancer patients, as it does not seem to facilitate in locoregionally staging the disease.

Publication
The influence of endorectal filling on rectal cancer staging with MRI.
Stijns RC, Scheenen TW, de Wilt JH, Fütterer JJ, Beets-Tan RG.
 

Related news items


Mathias Prokop appointed department head of Radiology UMCG He also remains department head of Imaging Radboudumc

11 April 2022 As of May 1, Mathias Prokop will become Department Head of Radiology at UMCG. He will fulfill this role in addition to his current position as Professor and Department Head of Imaging at the Radboudumc. Jurgen Fütterer will assume the daily management of the Radboudumc clinic. read more

Thomas van den Heuvel wins Stairway to Impact Award for safer pregnancies using AI Award for safer pregnancies using AI

1 December 2021 Radboudumc researcher Thomas van den Heuvel receives the Stairway to Impact Award from Dutch Research Council NWO. He receives this prize for the development of the BabyChecker, a smartphone application that allows midwives to make ultrasounds during pregnancies. read more

Chella van der Post and Francesco Ciompi received a grant from Hanarth Foundation

11 November 2021 Unmasking the invisible cancer: digital detection of diffuse-type gastric carcinomas. read more

KWF grant for better selection of individuals and lung nodules in lung cancer screening

1 November 2021 The Dutch Cancer Society has awarded the consortium project ‘Multi-source data approach for Personalized Outcome Prediction in lung cancer screening’ with a grant of 1,425,000 Euro. Colin Jacobs will lead the work package on using artificial intelligence for accurate risk estimation of lung nodules. read more

New ultra-high field MRI system available for Radboudumc and Radboud University

10 June 2021 Recently, the Hahn institute in Essen has received a new heart: a 20-ton ultra-high-field MRI scanner from Siemens Healthcare with a magnetic field strength of 7 Tesla. The new CE-approved scanner is ready for business, and projects on body and brain imaging are starting up. read more

Awarded KWF grants for Radboudumc researchers

18 December 2019 KWF is investing 2.7 million euros in five different studies at Radboudumc. The awards are part of the new round of funding by DCS, in which over 34 million euros will be granted to Dutch cancer research. We congratulate our researchers with this funding and wish them success with their great work. read more